Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inchinkoto (TJ-135) is a traditional Japanese Kampo medicine composed of three specific herbal extracts: *Artemisiae Capillaris Herba* (Inchinko), *Gardeniae Fructus* (Sanshishi), and *Rhei Rhizoma* (Daio). It is widely used in Japan for the treatment of jaundice, liver disorders, and biliary conditions. The drug exerts its therapeutic effects primarily through choleretic activity, which involves increasing bile flow and promoting the excretion of bilirubin and bile acids. Pharmacologically, Inchinkoto acts as an inducer of the multidrug resistance-associated protein 2 (MRP2) and an agonist of the farnesoid X receptor (FXR), both of which are critical for bile homeostasis. Additionally, it has demonstrated anti-inflammatory and anti-fibrotic properties in various liver disease models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inchinkoto.